Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Frovatriptan Succinate
Generic Name
Frovatriptan Succinate
Active Ingredient
FrovatriptanCategory
Other
Salt Form
Succinate
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 2.5 mg/1 | TABLET, FILM COATED | ORAL | 68462-694 |
Detailed information about Frovatriptan Succinate
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Frovatriptan Succinate, you must consult a qualified healthcare professional.
Frovatriptan is a selective serotonin receptor agonist (triptan) indicated for the acute treatment of migraine attacks with or without aura in adults.
The standard recommended dose for the acute treatment of migraine in adults is a single 2.5 mg tablet. Clinical trials have demonstrated that higher single doses (e.g., 5 mg or 10 mg) do not provide significantly greater pain relief but do increase the risk of adverse effects.
If the migraine headache returns after an initial successful response, a second 2.5 mg dose may be taken, provided that at least two hours have elapsed since the first dose. The maximum total daily dose of Frovatriptan must not exceed 7.5 mg (three 2.5 mg tablets) in any 24-hour period. If the first dose of Frovatriptan does not provide any relief, the diagnosis of migraine should be reconsidered before a second dose is administered for the same attack.
The safety and effectiveness of Frovatriptan in pediatric patients (under 18 years of age) have not been established. Consequently, Frovatriptan is not approved for use in children or adolescents. Clinical studies in pediatric populations for other triptans have shown different efficacy profiles than in adults, and healthcare providers generally avoid prescribing Frovatriptan to this age group unless specifically indicated under specialist supervision.
No dosage adjustment is generally required for patients with renal impairment. While approximately 40% of the drug is cleared renally, clinical data suggests that even in cases of significant renal dysfunction, the systemic exposure to Frovatriptan does not increase to a level requiring dose modification.
For patients with mild to moderate hepatic impairment, no adjustment of the initial dose is necessary. However, because Frovatriptan is extensively metabolized by the liver, it should be used with extreme caution in patients with severe hepatic impairment. In such cases, the liver's ability to clear the drug is reduced, potentially leading to higher plasma concentrations and an increased risk of side effects.
Clinical studies of Frovatriptan did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Frovatriptan should be taken as soon as the migraine headache begins. It can be taken with or without food. The tablet should be swallowed whole with a full glass of water or other liquid. Do not crush, chew, or break the tablet, as this may affect the absorption rate and the taste.
Patients should keep a headache diary to track when they take Frovatriptan and the effectiveness of the medication. This information is vital for the healthcare provider to assess whether the treatment plan is working or if adjustments are needed. Frovatriptan should be stored at room temperature, between 68°F and 77°F (20°C to 25°C), away from moisture and heat.
Frovatriptan is taken only as needed for acute migraine attacks and is not intended for daily or scheduled use. If you are using it off-label for menstrual migraine prophylaxis and miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.
There is no specific antidote for Frovatriptan overdose. In the event of an overdose, the patient should be monitored for at least 48 hours or while symptoms persist. Monitoring should include the cardiovascular system, as triptans can cause coronary vasospasm and hypertension. Standard supportive treatment, including gastric lavage or activated charcoal if appropriate, should be administered. Because of the long half-life of Frovatriptan, symptoms of toxicity may be prolonged.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency of use without medical guidance. Overusing migraine medications (taking them 10 or more days per month) can lead to 'medication overuse headache,' a condition where the medication actually causes more frequent headaches.
While Frovatriptan is generally well-tolerated, some patients may experience mild to moderate side effects. These typically occur shortly after taking the medication and are usually transient. Common side effects include:
> Warning: Stop taking Frovatriptan and call your doctor or seek emergency medical care immediately if you experience any of the following:
The primary concern with long-term, frequent use of Frovatriptan is the development of Medication Overuse Headache (MOH). If Frovatriptan is used on 10 or more days per month, the brain may become sensitized, leading to a cycle where the headache returns as soon as the medication wears off. This can transform episodic migraines into chronic daily headaches. Patients should also be monitored for potential changes in blood pressure over long-term use.
There are currently no FDA black box warnings for Frovatriptan. However, the class-wide warnings for triptans regarding cardiovascular risks are strictly enforced in the professional labeling. This includes the prohibition of use in patients with known coronary artery disease or uncontrolled hypertension.
Report any unusual symptoms to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.
Frovatriptan is strictly intended for the acute treatment of migraine attacks that have already begun. It should not be used for other types of headaches, such as hemiplegic or basilar migraines, because these patients are at a higher risk of stroke. Patients should be advised that Frovatriptan does not reduce the number of migraine attacks they have; it only treats the symptoms of an active attack.
No FDA black box warnings for Frovatriptan. However, it carries significant warnings regarding cardiovascular and cerebrovascular safety that are common to the triptan class.
For most healthy patients, routine laboratory monitoring is not required specifically for Frovatriptan. However, for patients with cardiovascular risk factors, periodic ECG monitoring and blood pressure checks are recommended. If a patient is taking Frovatriptan long-term or frequently, healthcare providers may monitor liver and kidney function to ensure the drug is being cleared effectively.
Migraine itself, as well as treatment with Frovatriptan, may cause somnolence (drowsiness) or dizziness. Patients should be cautioned against performing complex tasks, such as driving or operating heavy machinery, until they are certain that the medication does not impair their ability to do so safely.
Alcohol can be a powerful migraine trigger for many patients. Furthermore, alcohol may increase the sedative effects of Frovatriptan, leading to increased drowsiness or impaired coordination. It is generally recommended to avoid alcohol consumption during a migraine attack and while taking Frovatriptan.
Frovatriptan does not require a tapering schedule when used as directed for acute attacks. However, if a patient has been overusing the medication (leading to medication overuse headache), a structured withdrawal or 'washout' period may be necessary under medical supervision to break the cycle of chronic headaches.
> Important: Discuss all your medical conditions, especially any history of heart disease, stroke, or high blood pressure, with your healthcare provider before starting Frovatriptan.
There are no known significant interactions between Frovatriptan and common clinical laboratory tests. It does not typically interfere with standard blood chemistry, hematology, or urinalysis results.
For each major interaction, the mechanism usually involves either Pharmacodynamic synergy (two drugs doing the same thing to the body, like constricting vessels) or Pharmacokinetic interference (one drug changing how the body processes the other, usually via CYP1A2 inhibition). Management strategies typically involve separating doses by 24 hours or choosing alternative therapies.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as well as any changes in your smoking habits, as smoking can induce CYP1A2 and lower Frovatriptan levels.
Frovatriptan must NEVER be used in patients with the following conditions:
Patients who have had a severe allergic reaction (anaphylaxis, angioedema) to any other triptan (e.g., sumatriptan, naratriptan) should use Frovatriptan with extreme caution, as there is a theoretical risk of cross-sensitivity, although they are chemically distinct.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'chest heaviness' with other medications, before prescribing Frovatriptan.
Frovatriptan is classified under the former FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies (rats and rabbits), oral administration of frovatriptan during organogenesis resulted in increased incidences of fetal malformations and decreased fetal body weights at doses that were also maternally toxic. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Healthcare providers often recommend non-pharmacological treatments or older, better-studied medications as first-line options for pregnant patients with migraine.
It is not known whether Frovatriptan is excreted in human milk. In rats, frovatriptan is secreted in milk with levels up to four times higher than those in maternal plasma. Because many drugs are excreted in human milk, caution should be exercised when Frovatriptan is administered to a nursing woman. To minimize infant exposure, some experts suggest waiting 24 hours after taking a dose before resuming breastfeeding, utilizing the 'pump and dump' method during that window.
Frovatriptan is not FDA-approved for use in patients under the age of 18. The efficacy and safety in children have not been established. In clinical trials of other triptans in adolescents, the placebo response rate is often very high, making it difficult to prove superior efficacy. Additionally, the long-term effects on growth and development are unknown.
Clinical studies did not include enough subjects aged 65 and over to determine if they respond differently than younger subjects. However, because elderly patients are more likely to have underlying cardiovascular disease, decreased renal function, or hepatic impairment, the use of Frovatriptan in this population requires a thorough pre-treatment screening and cautious dosing. The pharmacokinetic profile in healthy elderly subjects is similar to that in younger adults.
While 40% of Frovatriptan is excreted via the kidneys, no dosage adjustment is necessary for patients with renal impairment. However, in patients with end-stage renal disease (ESRD) or those on dialysis, the clearance of the drug may be altered, and clinical monitoring for adverse effects is warranted. Frovatriptan is not expected to be significantly removed by hemodialysis due to its large volume of distribution.
No adjustment is needed for mild to moderate hepatic impairment (Child-Pugh grades A and B). In patients with severe hepatic impairment (Child-Pugh grade C), the metabolism of Frovatriptan is likely to be significantly reduced. There is limited clinical data for this group, and use is generally not recommended or should be approached with extreme caution.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning a pregnancy or are currently breastfeeding.
Frovatriptan is a selective agonist for the 5-hydroxytryptamine1 (5-HT1) receptor class. It exhibits a high affinity for the 5-HT1B and 5-HT1D receptors. The 5-HT1B receptors are primarily located on the smooth muscle of cranial blood vessels, where their activation leads to vasoconstriction. The 5-HT1D receptors are primarily located on the presynaptic terminals of the trigeminal nerve fibers. Activation of these receptors inhibits the release of pro-inflammatory neuropeptides (like CGRP), which prevents neurogenic inflammation and stops the transmission of pain signals to the brain's trigeminal nucleus.
The pharmacodynamic effect of Frovatriptan is characterized by its specific action on the intracranial vasculature rather than the systemic vasculature, although some systemic vasoconstriction can occur (leading to the contraindication in hypertension). The onset of pain relief usually begins within 30 to 60 minutes, but peak effect may take up to 2 to 4 hours. Because of its high receptor affinity and exceptionally slow dissociation from the receptor, its effects are prolonged.
| Parameter | Value |
|---|---|
| Bioavailability | 20% - 30% |
| Protein Binding | ~15% |
| Half-life | ~26 hours |
| Tmax | 2 - 4 hours |
| Metabolism | Hepatic (Primarily CYP1A2) |
| Excretion | Renal 40%, Fecal 60% |
Frovatriptan is classified as a 'Triptan' or a selective 5-HT1B/1D receptor agonist. It is part of the second generation of triptans, developed to improve upon the pharmacokinetic limitations of sumatriptan. Other drugs in this class include Almotriptan, Eletriptan, Naratriptan, Rizatriptan, Sumatriptan, and Zolmitriptan. Frovatriptan is distinguished within this class by having the longest half-life, which is clinically relevant for patients who experience long-lasting migraines or frequent headache recurrence.
Common questions about Frovatriptan Succinate
Frovatriptan is a prescription medication specifically used for the acute treatment of migraine headaches with or without aura in adults. It belongs to a class of drugs known as triptans, which work by narrowing blood vessels around the brain and stopping pain signals from being sent. It is important to note that Frovatriptan is only intended to treat a migraine that has already started and is not used to prevent migraines or treat other types of headaches like tension headaches. Some doctors may prescribe it off-label for the short-term prevention of menstrual-related migraines due to its long-lasting effects. It should not be used for hemiplegic or basilar migraines, which involve different risks. Always consult your healthcare provider to ensure an accurate diagnosis of your headache type before starting this medication.
The most common side effects reported by patients taking Frovatriptan include dizziness, fatigue, and a feeling of sleepiness or somnolence. Many patients also experience paresthesia, which is a tingling or 'pins and needles' sensation, typically in the hands, feet, or face. Other frequent symptoms include flushing (a sudden sense of warmth or redness), dry mouth, and mild indigestion or stomach upset. These side effects are usually mild and tend to go away on their own within a few hours as the medication processes through your system. However, if these symptoms persist or become bothersome, you should contact your healthcare provider. It is also important to distinguish these common effects from more serious symptoms like chest pressure or shortness of breath, which require immediate medical attention.
It is generally advised to avoid drinking alcohol while taking Frovatriptan for several important reasons. First, alcohol is a well-known trigger for migraine attacks in many individuals, and consuming it during an attack may worsen your symptoms or make the medication less effective. Second, both Frovatriptan and alcohol can cause dizziness and drowsiness; combining them can significantly increase these sedative effects, making it dangerous to drive or perform tasks requiring focus. Alcohol can also contribute to dehydration, which is often a factor in the severity of migraine headaches. While there is no direct chemical 'poisoning' interaction between the two, the combination usually leads to a poorer clinical outcome. If you have questions about your alcohol consumption habits, discuss them openly with your doctor.
The safety of Frovatriptan during pregnancy has not been fully established in humans, as there are no adequate and well-controlled studies in pregnant women. Animal studies have shown that high doses of the drug can lead to fetal malformations and lower birth weights, particularly when the dose is high enough to be toxic to the mother. Because of these potential risks, Frovatriptan is typically only used during pregnancy if the potential benefit to the mother clearly outweighs the potential risk to the developing fetus. Most healthcare providers recommend exploring safer, non-drug alternatives for migraine management during pregnancy first. If you are pregnant, planning to become pregnant, or find out you are pregnant while taking Frovatriptan, you must notify your healthcare provider immediately. They may suggest a different treatment plan or monitor your pregnancy more closely.
Frovatriptan typically begins to provide relief within 30 to 60 minutes after taking the tablet, but it may take up to 2 to 4 hours to reach its full effect. Compared to some other triptans like rizatriptan or sumatriptan, Frovatriptan has a slightly slower onset of action. However, its major advantage is its 'staying power'—because it has an exceptionally long half-life of 26 hours, the relief it provides often lasts much longer than other medications in its class. This makes it particularly useful for patients whose migraines tend to last for several days or for those who frequently experience a 'rebound' or recurrence of their headache within 24 hours. If you do not feel any relief after the first dose, do not take a second dose for the same attack without contacting your doctor, as your headache may not be a migraine.
Yes, you can stop taking Frovatriptan suddenly because it is an 'as-needed' medication for acute attacks and is not typically taken on a daily, long-term schedule. There is no physical withdrawal syndrome associated with stopping Frovatriptan like there is with some other types of medications (such as antidepressants or opioids). However, if you have been using Frovatriptan very frequently—specifically on 10 or more days per month—stopping it might initially cause your headaches to become more frequent or severe for a short period. This is known as a 'washout' period from medication overuse. If you find that you need to take Frovatriptan frequently, it is a sign that you should talk to your doctor about starting a daily preventive medication instead of relying solely on acute treatments.
Since Frovatriptan is taken only when you feel a migraine starting, you cannot truly 'miss' a dose in the way you would with a daily medication. You should simply take one 2.5 mg tablet as soon as you realize a migraine is beginning. If you are using Frovatriptan on a specific schedule for the short-term prevention of menstrual migraines and you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed one and continue with your regular timing. Never take two doses at once to make up for a missed one. Always ensure that at least two hours pass between any two doses of Frovatriptan, and never exceed more than three tablets (7.5 mg) in a 24-hour period.
Weight gain is not a recognized or common side effect of Frovatriptan. Clinical trials and post-marketing surveillance have not shown a significant link between the use of this medication and changes in body weight. Because Frovatriptan is taken intermittently (only during a migraine attack) rather than every day, it is unlikely to affect the metabolic processes or appetite in a way that would lead to weight gain. If you are experiencing unexplained weight changes while taking Frovatriptan, it may be due to other factors, such as other medications you are taking, changes in your activity level due to frequent migraines, or an underlying medical condition. You should discuss any significant changes in your weight with your healthcare provider to determine the cause.
Frovatriptan can interact with several other medications, some of which can cause serious complications. It should never be taken within 24 hours of using another triptan or any ergotamine-type medication, as this can cause dangerous constriction of the blood vessels. There is also a risk of a serious condition called serotonin syndrome if Frovatriptan is taken with certain antidepressants, such as SSRIs (like Prozac or Zoloft) or SNRIs (like Effexor). Additionally, some medications like oral contraceptives or certain antibiotics can increase the levels of Frovatriptan in your blood. Because of these risks, it is vital that you provide your doctor with a complete list of all the medications, vitamins, and herbal supplements you are currently taking before starting Frovatriptan.
Yes, Frovatriptan is available as a generic medication (frovatriptan succinate) as well as under the brand name Frova. Generic versions of medications are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove 'bioequivalence,' meaning they work in the body in the same way and provide the same clinical benefit. Choosing the generic version can often significantly reduce your out-of-pocket costs at the pharmacy. If you have concerns about switching from the brand-name to a generic version, or vice versa, you should discuss them with your pharmacist or healthcare provider to ensure you are comfortable with your treatment plan.
Other drugs with the same active ingredient (Frovatriptan)